Home Medicine The importance of laboratory medicine in the management of CKD-MBD: insights from the KDIGO 2023 controversies conference
Article
Licensed
Unlicensed Requires Authentication

The importance of laboratory medicine in the management of CKD-MBD: insights from the KDIGO 2023 controversies conference

  • Samuel D. Vasikaran ORCID logo EMAIL logo , Konstantinos Makris ORCID logo , Harjit Pal Bhattoa ORCID logo , Tomáš Zima ORCID logo , Pierre Delanaye ORCID logo , Pieter Evenepoel ORCID logo , Hanne Skou Jørgensen ORCID logo , Mathias Haarhaus ORCID logo , Eugene McCloskey ORCID logo , Giovanni Lombardi ORCID logo , Etienne Cavalier ORCID logo and On behalf of the IFCC Committee on Bone Metabolism and EFLM Committee on Chronic Kidney Disease
Published/Copyright: June 27, 2025
Clinical Chemistry and Laboratory Medicine (CCLM)
From the journal Clinical Chemistry and Laboratory Medicine (CCLM) Volume 63 Issue 12

Abstract

Laboratory investigations are important in the clinical management and the study of chronic kidney disease–mineral and bone disorder (CKD-MBD)- including CKD-associated osteoporosis. Parathyroid hormone (PTH) is the major hormone in the regulation of bone and calcium balance but is significantly affected in advanced CKD. Knowledge of PTH concentration is important in the assessment of osteoporosis including CKD-associated osteoporosis; however, measurement of PTH in the laboratory is bedevilled by interferences and inter-method differences compounded by lack of standardisation of commonly used immunoassays. Vitamin D is important for bone health and its deficiency contributes to the development of osteoporosis. Vitamin D metabolism is impaired in advanced CKD, augmenting the effects of its deficiency on bone health. Lack of consensus on optimal serum 25-hydroxyvitamin D (25-(OH)D) concentrations for bone health, including in the various CKD stages, is compounded by lack of analytical specificity of immunoassays. Liquid chromatography tandem mass spectrometry (LC-MS/MS) assays would help overcome these issues. Ionised calcium measurement is recommended for assessment of serum calcium, especially in CKD. Fibroblast growth factor 23 (FGF23) is important in the homeostasis of phosphate that accumulates in CKD, though this marker is not yet utilized in clinical context. Calculated maximal tubular reabsorption of phosphate normalized to glomerular filtration rate (TmP/GFR) may help in assessment of phosphate homeostasis. Bone specific alkaline phosphatase (BALP) and tartrate-resistant acid phosphatase isoform 5b (TRACP5b), the reference markers of bone formation and resorption for CKD-associated osteoporosis, have been shown to reflect bone turnover by histomorphometry in patients with advanced CKD.

Keywords: chronic kidney disease; osteoporosis; parathyroid hormone; vitamin D; bone turnover markers; fibroblast growth factor 23
Corresponding author: Samuel D. Vasikaran, Department of Clinical Biochemistry, PathWest-Fiona Stanley Hospital, Murdoch, WA, 6150, Australia; and PathWest Laboratory Medicine, Fiona Stanley Hospital, Murdoch, WA, Australia, E-mail:

Acknowledgments

IFCC-SD and EFLM C-CKD.

  1. Research ethics: Not applicable.

  2. Informed consent: Not applicable.

  3. Author contributions: Conceived by SV and EC, drafted by SV with major contribution from EC and additional contributions from KM,HPB, GL, TZ and PD. All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

  4. Use of Large Language Models, AI and Machine Learning Tools: None declared.

  5. Conflict of interest: KM.: Received free of charge reagents from ROCHE, SNIBE and IDS for research purposes; GL.: Received speaker fee from SNIBE; EC.: Consultant for IDS, DIASORIN, FUJIREBIO, NITTOBO and SNIBE. All other authors state no conflict of interest.

  6. Research funding: None declared.

  7. Data availability: Not applicable.

References

1. Ketteler, M, Evenepoel, P, Holden, RM, Isakova, T, Jørgensen, HS, Komaba, H, et al.. Conference participants. Chronic kidney disease-mineral and bone disorder: conclusions from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 2025;107:405–23. https://doi.org/10.1016/j.kint.2024.11.013.Search in Google Scholar PubMed

2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 clinical practice guideline update for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2017;7:1–59. https://doi.org/10.1016/j.kisu.2017.04.001.Search in Google Scholar PubMed PubMed Central

3. Malluche, HH, Porter, DS, Monier-Faugere, MC, Mawad, H, Pienkowski, D. Differences in bone quality in low- and high-turnover renal osteodystrophy. J Am Soc Nephrol 2012;23:525–32. https://doi.org/10.1681/asn.2010121253.Search in Google Scholar PubMed PubMed Central

4. Jansz, TT, Goto, NA, van Ballegooijen, AJ, Willems, HC, Verhaar, MC, van Jaarsveld, BC. The prevalence and incidence of vertebral fractures in end-stage renal disease and the role of parathyroid hormone. Osteoporos Int 2020;31:515–24. https://doi.org/10.1007/s00198-019-05187-0.Search in Google Scholar PubMed PubMed Central

5. Sturgeon, CM, Sprague, S, Almond, A, Cavalier, E, Fraser, WD, Algeciras-Schimnich, A, et al.. IFCC working group for PTH. perspective and priorities for improvement of parathyroid hormone (PTH) measurement - a view from the IFCC working group for PTH. Clin Chim Acta 2017;467:42–7. https://doi.org/10.1016/j.cca.2016.10.016.Search in Google Scholar PubMed PubMed Central

6. Cavalier, E, Vasikaran, S, Bhattoa, HP, Heijboer, AC, Makris, K, Ulmer, CZ. The path to the standardization of PTH: is this a realistic possibility? A position paper of the IFCC C-BM. Clin Chim Acta 2021;515:44–51. https://doi.org/10.1016/j.cca.2020.12.022.Search in Google Scholar PubMed PubMed Central

7. Farré-Segura, J, Le Goff, C, Lukas, P, Cobraiville, G, Fillet, M, Servais, AC, et al.. Validation of an LC-MS/MS method using solid-phase extraction for the quantification of 1-84 parathyroid hormone: toward a candidate reference measurement procedure. Clin Chem 2022;68:1399–409. https://doi.org/10.1093/clinchem/hvac135.Search in Google Scholar PubMed

8. Cavalier, E, Farré-Segura, J, Lukas, P, Gendebien, AS, Peeters, S, Massonnet, P, et al.. Unveiling a new era with liquid chromatography coupled with mass spectrometry to enhance parathyroid hormone measurement in patients with chronic kidney disease. Kidney Int 2024;105:338–46. https://doi.org/10.1016/j.kint.2023.09.033.Search in Google Scholar PubMed

9. Dupuy, AM, Bargnoux, AS, Morena, M, Lauret, E, Souberbielle, JC, Cavalier, E, et al.. Moving from the second to the third generation roche PTH assays: what are the consequences for clinical practice? Clin Chem Lab Med 2018;57:244–9. https://doi.org/10.1515/cclm-2018-0300.Search in Google Scholar PubMed

10. Gao, P, D’Amour, P. Evolution of the parathyroid hormone (PTH) assay--importance of circulating PTH immunoheterogeneity and of its regulation. Clin Lab 2005;51:21–9.Search in Google Scholar

11. Kritmetapak, K, Losbanos, LA, Hines, JM, O’Grady, KL, Ulmer, CZ, Vesper, HW, et al.. Chemical characterization and quantification of circulating intact PTH and PTH fragments by high-resolution mass spectrometry in chronic renal failure. Clin Chem 2021;67:843–53. https://doi.org/10.1093/clinchem/hvab013.Search in Google Scholar PubMed PubMed Central

12. Peacock, M. Effect of calcium and vitamin d insufficiency on the skeleton. Osteoporos Int 1998;8:S45–51.10.1007/PL00022733Search in Google Scholar

13. Cavalier, E, Makris, K, Heijboer, AC, Herrmann, M, Souberbielle, JC. Vitamin D: analytical advances, clinical impact, and ongoing debates on health perspectives. Clin Chem 2024;70:1104–21. https://doi.org/10.1093/clinchem/hvae056.Search in Google Scholar PubMed

14. Dirks, NF, Cavalier, E, Heijboer, AC. Vitamin d: marker, measurand and measurement. Endocr Connect 2023;12:e220269. https://doi.org/10.1530/EC-22-0269.Search in Google Scholar PubMed PubMed Central

15. Clarke, B. Normal bone anatomy and physiology. Clin J Am Soc Nephrol 2008;3:S131–9. https://doi.org/10.2215/cjn.04151206.Search in Google Scholar

16. Ong, GS, Walsh, JP, Stuckey, BG, Brown, SJ, Rossi, E, Ng, JL, et al.. The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism. J Clin Endocrinol Metab 2012;97:3138–45. https://doi.org/10.1210/jc.2012-1429.Search in Google Scholar PubMed

17. Labriola, L, Wallemacq, P, Gulbis, B, Jadoul, M. The impact of the assay for measuring albumin on corrected (‘adjusted’) calcium concentrations. Nephrol Dial Transplant 2009;24:1834–8. https://doi.org/10.1093/ndt/gfn747.Search in Google Scholar PubMed

18. Heijboer, AC, Cavalier, E. The measurement and interpretation of fibroblast growth factor 23 (FGF23) concentrations. Calcif Tissue Int 2023;112:258–70. https://doi.org/10.1007/s00223-022-00987-9.Search in Google Scholar PubMed PubMed Central

19. Kritmetapak, K, Kumar, R. Phosphatonins: from discovery to therapeutics. Endocr Pract 2023;29:69–79. https://doi.org/10.1016/j.eprac.2022.09.007.Search in Google Scholar PubMed

20. Payne, RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem 1998;35:201–6. https://doi.org/10.1177/000456329803500203.Search in Google Scholar PubMed

21. Peacock, M. Phosphate metabolism in health and disease. Calcif Tissue Int 2021;108:3–15. https://doi.org/10.1007/s00223-020-00686-3.Search in Google Scholar PubMed

22. Vasikaran, S, Eastell, R, Bruyère, O, Foldes, AJ, Garnero, P, Griesmacher, A, et al.. IOF-IFCC bone marker standards working group. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 2011;22:391–420. https://doi.org/10.1007/s00198-010-1501-1.Search in Google Scholar PubMed

23. Bhattoa, HP, Vasikaran, S, Trifonidi, I, Kapoula, G, Lombardi, G, Jørgensen, NR, et al.. Update on the role of bone turnover markers in the diagnosis and management of osteoporosis: a consensus paper from the european society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO), international osteoporosis foundation (IOF), and international Federation of clinical chemistry and laboratory medicine (IFCC). Osteoporos Int 2025;36:579–608. https://doi.org/10.1007/s00198-025-07422-3.Search in Google Scholar PubMed PubMed Central

24. Jean, G, Souberbielle, JC, Zaoui, E, Lorriaux, C, Mayor, B, Hurot, JM, et al.. Total and bone-specific alkaline phosphatases in haemodialysis patients with chronic liver disease. Clin Biochem 2012;45:436–9. https://doi.org/10.1016/j.clinbiochem.2012.01.018.Search in Google Scholar PubMed

25. Kashgary, A, Attiah, FOA, AlKhateeb, NA, Abdulaziz, NH, Alsaif, BA, Aljuhani, AF, et al.. Incidence of bone fractures among patients on maintenance hemodialysis. Ren Fail 2023;45:2224456. https://doi.org/10.1080/0886022x.2023.2224456.Search in Google Scholar

26. Matias, PJ, Laranjinha, I, Azevedo, A, Raimundo, A, Navarro, D, Jorge, C, et al.. Bone fracture risk factors in prevalent hemodialysis patients. J Bone Miner Metabol 2020;38:205–12. https://doi.org/10.1007/s00774-019-01041-9.Search in Google Scholar PubMed

27. Iimori, S, Mori, Y, Akita, W, Kuyama, T, Takada, S, Asai, T, et al.. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study. Nephrol Dial Transplant 2012;27:345–51. https://doi.org/10.1093/ndt/gfr317.Search in Google Scholar PubMed

28. Maruyama, Y, Taniguchi, M, Kazama, JJ, Yokoyama, K, Hosoya, T, Yokoo, T, et al.. Higher serum alkaline phosphatase is associated with the incidence of hip fracture and mortality among patients receiving hemodialysis in Japan. Nephrol Dial Transplant 2014;29:1532–8. https://doi.org/10.1093/ndt/gfu055.Search in Google Scholar PubMed

29. Feenstra, L, Reijrink, M, Pasch, A, Smith, ER, Visser, LM, Bulthuis, M, et al.. TransplantLines investigators. Calciprotein particle counts associate with vascular remodelling in chronic kidney disease. Cardiovasc Res 2024;120:1953–66. https://doi.org/10.1093/cvr/cvae164.Search in Google Scholar PubMed PubMed Central

30. Miura, Y, Kurosu, H, Kuro-O, M. Quantification of calciprotein particles (CPPs) in serum/plasma samples using a fluorescent bisphosphonate. Methods Mol Biol 2023;2664:333–41. https://doi.org/10.1007/978-1-0716-3179-9-21.Search in Google Scholar

31. Bundy, JD, Cai, X, Mehta, RC, Scialla, JJ, de Boer, IH, Hsu, CY, et al.. CRIC study investigators. Serum calcification propensity and clinical events in CKD. Clin J Am Soc Nephrol 2019;14:1562–71. https://doi.org/10.2215/cjn.04710419.Search in Google Scholar PubMed PubMed Central

Received: 2025-06-27
Accepted: 2025-08-03
Published Online: 2025-06-27
Published in Print: 2025-11-25

© 2025 Walter de Gruyter GmbH, Berlin/Boston

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Challenging the dogma: why reviewers should be allowed to use AI tools
  4. Multivariate approaches to improve the interpretation of laboratory data
  5. Review
  6. Interference of therapeutic monoclonal antibodies with electrophoresis and immunofixation of serum proteins: state of knowledge and systematic review
  7. Opinion Papers
  8. Urgent call to the European Commission to simplify and contextualize IVDR Article 5.5 for tailored and precision diagnostics
  9. The importance of laboratory medicine in the management of CKD-MBD: insights from the KDIGO 2023 controversies conference
  10. Supplementation of pyridoxal-5′-phosphate in aminotransferase reagents: a matter of patient safety
  11. HCV serology: an unfinished agenda
  12. From metabolic profiles to clinical interpretation: multivariate approaches to population-based and personalized reference intervals and reference change values
  13. Genetics and Molecular Diagnostics
  14. A multiplex allele specific PCR capillary electrophoresis (mASPCR-CE) assay for simultaneously analysis of SMN1/SMN2/NAIP copy number and SMN1 loss-of-function variants
  15. General Clinical Chemistry and Laboratory Medicine
  16. From assessment to action: experience from a quality improvement initiative integrating indicator evaluation and adverse event analysis in a clinical laboratory
  17. Evaluation of measurement uncertainty of 11 serum proteins measured by immunoturbidimetric methods according to ISO/TS 20914: a 1-year laboratory data analysis
  18. Assessing the harmonization of current total vitamin B12 measurement methods: relevance and implications
  19. The current status of serum insulin measurements and the need for standardization
  20. Method comparison of plasma and CSF GFAP immunoassays across multiple platforms
  21. Cerebrospinal fluid leptin in Alzheimer’s disease: relationship to plasma levels and to cerebrospinal amyloid
  22. Verification of the T50 Calciprotein Crystallization test: bias estimation and interferences
  23. An innovative immunoassay for accurate aldosterone quantification: overcoming low-level inaccuracy and renal dysfunction-associated interference
  24. Oral salt loading combined with postural stimulation tests for confirming and subtyping primary aldosteronism
  25. Evaluating the performance of a multiparametric IgA assay for celiac disease diagnosis
  26. Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels
  27. Reference Values and Biological Variations
  28. Establishment of region-, age- and sex-specific reference intervals for aldosterone and renin with sandwich chemiluminescence immunoassays
  29. Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation
  30. Comparative analysis of population-based and personalized reference intervals for biochemical markers in peri-menopausal women: population from the PALM cohort study
  31. Hematology and Coagulation
  32. Evaluation of stability and potential interference on the α-thalassaemia early eluting peak and immunochromatographic strip test for α-thalassaemia --SEA carrier screening
  33. Cardiovascular Diseases
  34. Analytical and clinical evaluation of an automated high-sensitivity cardiac troponin I assay for whole blood
  35. Diabetes
  36. Method comparison of diabetes mellitus associated autoantibodies in serum specimens
  37. Letters to the Editor
  38. Permitting disclosed AI assistance in peer review: parity, confidentiality, and recognition
  39. Response to the editorial by Karl Lackner
  40. Hemolysis detection using the GEM 7000 at the point of care in a pediatric hospital setting: does it affect outcomes?
  41. Estimation of measurement uncertainty for free drug concentrations using ultrafiltration
  42. Cryoglobulin pre-analysis over the weekend
  43. Accelerating time from result to clinical action: impact of an automated critical results reporting system
  44. Recent decline in patient serum folate test levels using Roche Diagnostics Folate III assay
  45. Kidney stones consisting of 1-methyluric acid
  46. Congress Abstracts
  47. 7th EFLM Conference on Preanalytical Phase
  48. Association of Clinical Biochemists in Ireland Annual Conference
  49. Association of Clinical Biochemists in Ireland Annual Conference
  50. 17th Congress of the Portuguese Society of Clinical Chemistry, Genetics and Laboratory Medicine
https://doi.org/10.1515/cclm-2025-0802
Keywords for this article
chronic kidney disease; osteoporosis; parathyroid hormone; vitamin D; bone turnover markers; fibroblast growth factor 23

Articles in the same Issue

  1. Frontmatter
  2. Editorials
  3. Challenging the dogma: why reviewers should be allowed to use AI tools
  4. Multivariate approaches to improve the interpretation of laboratory data
  5. Review
  6. Interference of therapeutic monoclonal antibodies with electrophoresis and immunofixation of serum proteins: state of knowledge and systematic review
  7. Opinion Papers
  8. Urgent call to the European Commission to simplify and contextualize IVDR Article 5.5 for tailored and precision diagnostics
  9. The importance of laboratory medicine in the management of CKD-MBD: insights from the KDIGO 2023 controversies conference
  10. Supplementation of pyridoxal-5′-phosphate in aminotransferase reagents: a matter of patient safety
  11. HCV serology: an unfinished agenda
  12. From metabolic profiles to clinical interpretation: multivariate approaches to population-based and personalized reference intervals and reference change values
  13. Genetics and Molecular Diagnostics
  14. A multiplex allele specific PCR capillary electrophoresis (mASPCR-CE) assay for simultaneously analysis of SMN1/SMN2/NAIP copy number and SMN1 loss-of-function variants
  15. General Clinical Chemistry and Laboratory Medicine
  16. From assessment to action: experience from a quality improvement initiative integrating indicator evaluation and adverse event analysis in a clinical laboratory
  17. Evaluation of measurement uncertainty of 11 serum proteins measured by immunoturbidimetric methods according to ISO/TS 20914: a 1-year laboratory data analysis
  18. Assessing the harmonization of current total vitamin B12 measurement methods: relevance and implications
  19. The current status of serum insulin measurements and the need for standardization
  20. Method comparison of plasma and CSF GFAP immunoassays across multiple platforms
  21. Cerebrospinal fluid leptin in Alzheimer’s disease: relationship to plasma levels and to cerebrospinal amyloid
  22. Verification of the T50 Calciprotein Crystallization test: bias estimation and interferences
  23. An innovative immunoassay for accurate aldosterone quantification: overcoming low-level inaccuracy and renal dysfunction-associated interference
  24. Oral salt loading combined with postural stimulation tests for confirming and subtyping primary aldosteronism
  25. Evaluating the performance of a multiparametric IgA assay for celiac disease diagnosis
  26. Clinical significance of anti-mitochondrial antibodies and PBC-specific anti-nuclear antibodies in evaluating atypical primary biliary cholangitis with normal alkaline phosphatase levels
  27. Reference Values and Biological Variations
  28. Establishment of region-, age- and sex-specific reference intervals for aldosterone and renin with sandwich chemiluminescence immunoassays
  29. Validation of a plasma GFAP immunoassay and establishment of age-related reference values: bridging analytical performance and routine implementation
  30. Comparative analysis of population-based and personalized reference intervals for biochemical markers in peri-menopausal women: population from the PALM cohort study
  31. Hematology and Coagulation
  32. Evaluation of stability and potential interference on the α-thalassaemia early eluting peak and immunochromatographic strip test for α-thalassaemia --SEA carrier screening
  33. Cardiovascular Diseases
  34. Analytical and clinical evaluation of an automated high-sensitivity cardiac troponin I assay for whole blood
  35. Diabetes
  36. Method comparison of diabetes mellitus associated autoantibodies in serum specimens
  37. Letters to the Editor
  38. Permitting disclosed AI assistance in peer review: parity, confidentiality, and recognition
  39. Response to the editorial by Karl Lackner
  40. Hemolysis detection using the GEM 7000 at the point of care in a pediatric hospital setting: does it affect outcomes?
  41. Estimation of measurement uncertainty for free drug concentrations using ultrafiltration
  42. Cryoglobulin pre-analysis over the weekend
  43. Accelerating time from result to clinical action: impact of an automated critical results reporting system
  44. Recent decline in patient serum folate test levels using Roche Diagnostics Folate III assay
  45. Kidney stones consisting of 1-methyluric acid
  46. Congress Abstracts
  47. 7th EFLM Conference on Preanalytical Phase
  48. Association of Clinical Biochemists in Ireland Annual Conference
  49. Association of Clinical Biochemists in Ireland Annual Conference
  50. 17th Congress of the Portuguese Society of Clinical Chemistry, Genetics and Laboratory Medicine
Sign up now to receive a 20% welcome discount
Institutional Access
How does access work?
Have an idea on how to improve our website?
Please write us.
© 2025 De Gruyter Brill
Downloaded on 29.12.2025 from https://www.degruyterbrill.com/document/doi/10.1515/cclm-2025-0802/html
Scroll to top button